This MUC1 VLP vaccine induces higher levels of specific antibodies and prolongs the survival of tumor-bearing mice.293 Several VLP-based vaccines have successfully entered clinical trials, including the chikungunya vaccine, influenza vaccine, Neocon vaccine, cancer, encephalitis and other vaccines (Table 2).294 Notably, due to the highly ordered and repetitive spatial structure of VLPs, which is highly conducive to cross-linking BCRs, the VLPs vaccines can strongly activate B cells even in the absence of T helper (Th) cells.288. The gene discussed is MUC1; the disease is neoplasm.